Cholangiocellular hepatoma – pipeline review, h2 2012
Upcoming SlideShare
Loading in...5
×
 

Cholangiocellular hepatoma – pipeline review, h2 2012

on

  • 231 views

2012 || Pipeline Review, H2 2012 || Cholangiocellular Hepatoma – Pipeline Review, H2 2012 || Aarkstore.com

2012 || Pipeline Review, H2 2012 || Cholangiocellular Hepatoma – Pipeline Review, H2 2012 || Aarkstore.com

Statistics

Views

Total Views
231
Views on SlideShare
231
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Cholangiocellular hepatoma – pipeline review, h2 2012 Cholangiocellular hepatoma – pipeline review, h2 2012 Document Transcript

  • Aarkstore.com announces, The Latest market research report is available inits vast collection:Cholangiocellular Hepatoma – Pipeline Review, H2 2012http://www.aarkstore.com/reports/Cholangiocellular-Hepatoma-Pipeline-Review-H2-2012-220600.htmlRSS link of Global Markets Directhttp://www.aarkstore.com/feeds/Global-Markets-Direct.xmlSummaryGlobal Markets Direct’s, Cholangiocellular Hepatoma - Pipeline Review, H2 2012,provides an overview of the Cholangiocellular Hepatoma therapeutic pipeline. Thisreport provides information on the therapeutic development for CholangiocellularHepatoma, complete with latest updates, and special features on late-stage anddiscontinued projects. It also reviews key players involved in the therapeuticdevelopment for Cholangiocellular Hepatoma. Cholangiocellular Hepatoma -Pipeline Review, H2 2012 is built using data and information sourced from GlobalMarkets Direct’s proprietary databases, Company/University websites, SEC filings,investor presentations and featured press releases from company/university sitesand industry-specific third party sources, put together by Global Markets Direct’steam.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Cholangiocellular Hepatoma.- A review of the Cholangiocellular Hepatoma products under development bycompanies and universities/research institutes based on information derived from
  • company and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.- Coverage of the Cholangiocellular Hepatoma pipeline on the basis of route ofadministration and molecule type.- Profiles of late-stage pipeline products featuring sections on product description,mechanism of action and research & development progress.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Table of contents:List of Tables 3List of Figures 3Introduction 4Global Markets Direct Report Coverage 4Cholangiocellular Hepatoma Overview 5Therapeutics Development 6An Overview of Pipeline Products for Cholangiocellular Hepatoma 6Late Stage Products 8Comparative Analysis 8Cholangiocellular Hepatoma Therapeutics – Products under Investigation byUniversities/Institutes 9Assessment by Combination Products 10Assessment by Molecule Type 11Drug Profiles 13Cisplatin + Gemcitabine + Epirubicin - Drug Profile 13Product Description 13Mechanism of Action 13R&D Progress 13Appendix 14Methodology 14Coverage 14Secondary Research 14Primary Research 14
  • Expert Panel Validation 14Contact Us 15Disclaimer 15List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1Cholangiocellular Hepatoma – Pipeline Review, H2 2012Hormone Refractory Breast Cancer – Pipeline Review, H2 2012Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012Refractory Multiple Myeloma – Pipeline Review, H2 2012Epithelial Ovarian Cancer – Pipeline Review, H2 2012Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012B-Cell Leukemia – Pipeline Review, H2 2012Malignant Neoplasms – Pipeline Review, H2 2012
  • Recurrent Malignant Glioma – Pipeline Review, H2 2012Endobronchial Cancer – Pipeline Review, H2 2012Leiomyosarcoma – Pipeline Review, H2 2012Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012Esophageal Tumor – Pipeline Review, H2 2012Malignant Pleural Mesothelioma – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1You can also request for sample page of above mention reports onsample@aarkstore.comFor More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: enquiry@aarkstore.com